Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$195.00 USD

195.00
835,822

-5.82 (-2.90%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $195.12 +0.12 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Varian (VAR) to Boost Cancer Treatment With New Partnership

by Zacks Equity Research

Varian (VAR) expects to enhance cancer care with the new collaboration with IAEA, which is likely to drive Varian's core Oncology business.

ResMed (RMD) Rides on Strong SaaS Growth & New Product Suite

by Zacks Equity Research

ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.

Integra Partners AI-Driven Data Analytics Firm in Wound Care

by Zacks Equity Research

Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.

Phibro Animal Sees Crucial Progress in ASF Vaccine Development

by Zacks Equity Research

The identification of a group of peptides and proteins is a remarkable step toward Phibro's (PAHC) development of a solution for ASF.

Fresenius Set for Global Expansion of Research Activities

by Zacks Equity Research

Fresenius Medical Care (FMS) aims to expand the scope of its clinical research activities through an integration move.

Illumina (ILMN) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Illumina (ILMN) gains from expansion of its product portfolio and strategic partnership.

CVS Health Banks on Aetna Prospects, Omnicare May Disappoint

by Zacks Equity Research

CVS Health's (CVS) Aetna integration synergies bode well for the stock.

Boston Scientific to Sell Bead Suit, Make Way for BTG Buyout

by Zacks Equity Research

The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.

Here's Why CVS Health (CVS) Should Be in Your Portfolio

by Zacks Equity Research

Investors' trust continues to be high in CVS Health (CVS), thanks to strength in its PBM business.

Here's Why Chemed (CHE) Should Remain in Your Portfolio Now

by Zacks Equity Research

Investors' trust in Chemed (CHE) continues to be high, banking on its sturdy segmental performance.

Edwards Lifesciences Recalls Heart Device on Balloon Rupture

by Zacks Equity Research

Shares of Edwards Lifesciences (EW) decline post product recall news.

Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio

by Zacks Equity Research

With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.

Varian to Acquire Boston Scientific's Embolic Bead Products

by Zacks Equity Research

Varian (VAR) expects the buyout to prove accretive to its fiscal 2020 reported and adjusted earnings per share.

Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues

by Zacks Equity Research

Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.

Medtronic's Titan Spine Buyout to Boost Spine Surgery Range

by Zacks Equity Research

Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.

Walgreens Gains on Strategic Deals, Margin Pressure Remains

by Zacks Equity Research

Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.

Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics

by Zacks Equity Research

The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.

Here's Why You Should Hold Varian Medical (VAR) Stock Now

by Zacks Equity Research

Varian (VAR) expects the Cancer Treatment Services International buyout to prove accretive to earnings per share during fiscal 2021.

Amedisys Rides on New Buyouts, Strength in Personal Care Arm

by Zacks Equity Research

Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.

Veeva's Vault eTMF Implemented by South Korea's Celltrion

by Zacks Equity Research

Management at Veeva (VEEV) expects Vault subscription revenues to grow a significant 40% in fiscal 2020.

Walgreens Boots (WBA) Q3 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Walgreens Boots' (WBA) Retail Pharmacy USA division gains traction from comparable prescription volume growth and a sturdy retail prescription market.

Boston Scientific Strong on Growth Goals and Future Launches

by Zacks Equity Research

This long-range strategy will aid Boston Scientific (BSX) to deliver a solid financial footing across its MedSurg, Rhythm and Neuro plus Cardiovascular segments.

Varian (VAR) & Tennessee Oncology to Implement Use of Noona

by Zacks Equity Research

Varian's (VAR) core Oncology unit gets a boost from the latest collaboration with Tennessee Oncology.

Here's Why You Should Add Bruker (BRKR) to Your Portfolio

by Zacks Equity Research

Investor confidence in Bruker stock (BRKR) is high on substantial potential of MALDI Biotyper.

Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY (XRAY) focuses on innovation through active R&D.